Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of nesiritide injection in China. Welcome to wholesale bulk high quality nesiritide injection for sale here from our factory. Good service and reasonable price are available.
Nesiritide Injection is a specialized intravenous intervention drug developed specifically for the acute exacerbation of severe heart failure in the field of patient-related cardiovascular emergency diagnosis and intervention. It has clear efficacy in both patient-related utilization scope and pharmacological action direction. This article adheres to the principle of specific and rigorous exposition, focusing on the key diuretic and sodium excretion regulation mechanism, cardiac filling pressure regulation and emergency symptom relief effect, exclusive patient-related applicable population, drug efficacy characteristics, and routine controllable adverse reactions of the drug. It interprets the five key contents of the drug, restores the key value and basic medication points of the drug in patient-related practice, and provides clear and boundary specific references for patient-related diagnosis, intervention, and pharmaceutical reference for your selection.
Our Products
 |
 |
Nesiritide COA
 |
||
| Certificate of Analysis | ||
| Compound name | Nesiritide | |
| Grade | Pharmaceutical grade | |
| CAS No. | 124584-08-3 | |
| Quantity | 36g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202501090068 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.54% |
| Loss on drying | ≤1.0% | 0.42% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.98% |
| Single impurity | <0.8% | 0.52% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Store in a sealed, dark, and dry place below -20°C | |
|
|
||
|
|
||
| Chemical Formula | C143H244N50O42S4 |
| Exact Mass | 3462 |
| Molecular Weight | 3464 |
| m/z | 3463 (100.0%), 3464 (76.8%), 3462 (64.7%), 3465 (25.4%), 3464 (18.5%), 3465 (18.1%), 3466 (13.9%), 3465 (13.6%), 3465 (12.7%), 3466 (12.2%), 3463 (11.9%), 3464 (11.7%), 3465 (8.6%), 3466 (6.6%), 3464 (5.6%), 3466 (4.8%), 3467 (4.6%), 3467 (4.1%), 3466 (3.3%), 3464 (3.2%), 3464 (2.8%), 3466 (2.6%), 3467 (2.5%), 3465 (2.5%), 3467 (2.3%), 3466 (2.3%), 3468 (2.2%), 3467 (2.2%), 3467 (2.2%), 3465 (2.2%), 3463 (2.1%), 3463 (1.8%), 3465 (1.7%), 3464 (1.6%), 3466 (1.6%), 3467 (1.6%), 3465 (1.5%), 3465 (1.4%), 3465 (1.2%), 3467 (1.2%), 3468 (1.2%), 3467 (1.2%), 3467 (1.1%), 3464 (1.1%), 3468 (1.1%), 3463 (1.0%), 3468 (1.0%), 3465 (1.0%), 3466 (1.0%), 3466 (1.0%) |
| Elemental Analysis | C, 49.58; H, 7.10; N, 20.22; O, 19.40; S, 3.70 |
Diuretics and sodium excretion: increase urine output, reduce blood volume
- Diuretic and sodium excretion is one of the most fundamental key roles of this drug, with its target directly directed towards the body's water and salt metabolism. By regulating the renal excretion role, it achieves the elimination of excess water and sodium ions from the body.
- Increase urine output: drugs can promote the kidney to generate and discharge more urine, so that the water trapped in the body can be quickly discharged from the body through the urinary system, improve the urine output per unit time, and improve the state of water retention in the body.
- Reduce blood volume: As excess water is continuously excreted from the body, the total fluid volume in the systemic blood circulation will correspondingly decrease, directly reducing the circulating blood volume. Excessive blood volume can increase the burden of pumping blood in the heart. By reducing blood volume, the capacity load on the heart can be alleviated from the root, creating a foundation for the recovery of heart role.
Source of information:
Wang Yajie, Teng Yue, Sun Hong Research progress on the use of Nasilide as a intervention for decompensated heart failure [J]. Chinese Journal of Cardiovascular Disease, 2007 (09): 701-703
Reduce heart filling pressure: relieve pulmonary congestion and breathing difficulties
- Cardiac filling pressure refers to the pressure inside the ventricles during diastole. In acute heart failure, the heart's pumping ability decreases, making it difficult for blood to flow out smoothly, resulting in an abnormal increase in cardiac chamber filling pressure.
- This drug can effectively reduce heart filling pressure and relieve abnormal conditions of high heart chamber pressure by regulating cardiac load, allowing the diastolic and systolic role of the heart to return to a relatively stable state.
- Relieve pulmonary congestion: When the heart filling pressure is too high, blood will accumulate in the pulmonary blood vessels, forming pulmonary congestion; After the decrease in filling pressure, the blood accumulated in the lungs can gradually flow back, and the pathological state of pulmonary congestion is directly improved.
- Relieve respiratory distress: Pulmonary congestion can compress the lungs, affecting their normal ventilation and air exchange role, leading to symptoms such as chest tightness, wheezing, and difficulty breathing in patients; With the reduction of pulmonary congestion and the restoration of lung gas exchange role, the patient's respiratory distress symptoms can be significantly relieved.
Source of information:
Fu Yi Nesiritide, a recombinant human B-type natriuretic peptide therapy for heart failure [J]. Foreign Medicine (Volume of Synthetic and Biochemical Drug Preparations), 2002 (04): 251-252
Used for hospitalized patients with acute decompensated heart failure
(I)Limitations on applicable conditions: Nesiritide Injection is only used for acute decompensated heart failure, which refers to patients with pre-existing heart failure who suddenly experience acute exacerbation of the condition, or sudden acute heart failure with rapid deterioration of cardiac role, and belong to cardiovascular emergencies.
(II)Target audience: Only applicable to hospitalized patients, not used in outpatient, home and other non inpatient scenarios. As acute decompensated heart failure is a critical emergency, multiple indicators such as electrocardiogram, blood pressure, and renal role need to be monitored in the hospital to ensure medication safety.
(III)Strictly exclusive usage scenario: only used for inpatient intervention of acute decompensated heart failure, not for long-term maintenance intervention of chronic heart failure, nor extended to the intervention of other heart diseases or non heart diseases. The patient-related utilization boundary is clear and strict.
Source of information:
National Pharmacopoeia Committee Patient-related Medication Guidelines for Pharmacopoeia of the People's Republic of China: Chemical Drugs and Biological Products (2015 Edition) [M]. Beijing: China Medical Science and Technology Press, 2017
Chen Xinqian, Jin Youyu, Tang Guang New Pharmacology (17th edition) [M]. Beijing: People's Health Publishing House, 2011
key characteristics of drug efficacy time
- As an emergency intervention drug, the speed of onset of Naxilitide is its key drug advantage, it suitable for the rapid intervention needs of acute heart failure emergencies. Its time effectiveness characteristics are distinct and prominent, as shown below:
- After intravenous administration of drugs, the pharmacological effects are triggered quickly and the onset rhythm is fast, which can quickly meet the emergency intervention needs of patients with acute heart failure. It can gradually play a key regulatory role without long waiting, meeting the timeliness requirements of emergency diagnosis and intervention.
Source of information:
FDA. Natrecor (Nesiritide) Prescribing Information[S]. 2019.
Common Adverse Drug Reaction Tips
During the patient-related utilization of Nesiritide Injection, there may be a few mild or controllable adverse reactions, with fixed types of reactions and no complex extensions. The overall incidence is controllable and only requires simple patient-related attention. The specific common adverse reactions are as follows:During medication, occasional physical discomfort such as hypotension, headache, and nausea may occur, and some patients may experience slight fluctuations in renal role indicators. The overall adverse reactions are singular, with no other rare or serious associated reactions.
Source of information:
Weeks S G. Nesiritide: The patient-related experience[J]. Canadian Journal of Cardiology,2009,25(10):589-592.
As a specialized intravenous drug developed only for severe heart failure emergencies in patient-related practice, Naxilitide has a highly specific patient-related positioning and action direction. It is a targeted intervention drug for hospitalized patients with acute decompensated heart failure, with no broad patient-related utilization scenarios or redundant pharmacological extension effects. The drug relies on two key mechanisms to exert emergency intervention effects.
On the one hand, it increases urine excretion and reduces circulating blood volume through the diuretic and sodium excretion pathway, thereby reducing the burden of circulatory overload from the root; On the other hand, by lowering heart filling pressure and effectively relieving pulmonary congestion, the most difficult respiratory distress emergency symptoms of patients can be quickly relieved. In addition, its key advantage of rapid effectiveness after intravenous administration can accurately adapt to the rapid intervention needs of acute heart failure emergencies, and maximize the timeliness requirements of patient-related emergency diagnosis and intervention.
References
Li Weimin, Li Yue Practical Heart Failure Studies [M]. Beijing: People's Health Press, 2016
Editorial Department of Chinese Journal of Hospital Pharmacy Safety evaluation of patient-related utilization of Naxilitide [J]. Chinese Journal of Hospital Pharmacy, 2008, 28 (15): 1297-1299
FAQ
- What type of drug is nesiritide injection?
It is an approved form of human B-type natriuretic peptide synthesized by using recombinant DNA techniques. It is prescribed for patients who have acute HF. Nesiritide has modest natriuretic properties and is a systemic vasodilator.
- Is it a vasodilator?
Nesiritide, recombinant human B-type natriuretic peptide, is an intravenous vasodilator that is used to treat acutely decompensated heart failure. In addition to its modest diuretic and natriuretic properties, it reduces intracardiac filling pressures, increases cardiac index and improves symptoms.
- Is nesiritide FDA approved?
This is FDA approved for the short-term intravenous intervention of patients with acutely decompensated congestive heart failure (CHF) who have dyspnea (shortness of breath) at rest or with minimal activity.
Hot Tags: nesiritide injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale